
Jingrong Tang
Featured in:
cell.com
Articles
-
1 week ago |
biorxiv.org | Olivia White |Zahra Aligabi |Kendall H. Burks |Jingrong Tang
AbstractCurrent lipid-lowering drugs are relatively ineffective in reducing low-density lipoprotein (LDL) cholesterol in patients with Familial Hypercholesterolemia (FH) due to a dysfunctional LDL receptor (LDLR). However, LDL cholesterol reductions have been achieved in FH patients using angiopoietin-like 3 (ANGPTL3) inhibitors, which act through an uncharacterized, LDLR-independent pathway that requires endothelial lipase (EL).
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →